Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rebate Pass-Through Would Lower, Not Raise, Medicare Spending – PhRMA

Executive Summary

Biopharma manufacturers dispute predictions that passing through rebates at the point-of-sale in Medicare Part D would increase government spending. Pharmacy benefit managers argue the policy would violate the Part D statute and the Trade Secrets Act.

You may also be interested in...



Part D Point-Of-Sale Rebates Losing Appeal? CBO Confirms Big Cost To Medicare

Congressional Budget Office agrees with the Office of Management and Budget that passing through negotiated rebates to Medicare Part D beneficiaries at the point-of-sale would significantly increase Medicare spending.

Point-Of-Sale Rebates In Part D Could Save Seniors $20bn, PhRMA Argues

PhRMA President Ubl discusses drug pricing advocacy priorities in Medicare Part D during media briefing.

The Ups and Downs Of US Drug Pricing Policy

If 2017 was the year of talk (tweets) on prescription drug pricing policy, 2018 is shaping up to be the year of action.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel